Forty years ago, investors and business speculators shuddered at the prospect of working with India's pharmaceutical industry.
The industry was plagued by archaic patent laws and insufficient infrastructure, and only multinational companies (MNCs) were
able to exploit its crude resources and monopolistic legal framework. Struggling in the shadows of these MNCs were the Indian
pharmaceutical entrepreneurs and a handful of producers. Because more than 70% of the pharmaceutical market value was in the
hands of MNCs, India's indigenous pharmaceutical industry was floundering. Its amount of exports was negligible, and the domestic
market outlook was bleak because of onerous government regulation.
The catalyst for change came in 1970 with the overhaul of India's legally accepted British Patent Act of 1911. In contrast
with the United Kingdom's own amendment to this act in 1949, India continued to operate in a manner that restricted the production
of major drugs under patent protection for twenty years. After the ratification of the Indian Patent Act in 1970, the golden
age of India's domestic pharmaceutical industry began. The industry's sales increased from a few hundred million dollars in
the early 1970s to almost $8 billion by mid 2006. Exports today reach $5 billion, and MNCs' market share of the overall production
has dropped below 30%. Overall, the Indian pharmaceutical industry now represents nearly 1.5% of India's gross domestic product
(GDP), and reported growth is slightly more than 10%. Analysts estimate India's pharmaceutical industry will grow at a compounded
annual growth rate (CAGR) of 13.6%, making revenue figures of more than $10 billion by 2010 a realistic projection.
The pharmaceutical industry is only one of the factors helping the Indian economy to reach record heights. The services industry
alone accounts for more than half of the country's GDP, and manufacturing and agriculture split the remaining share. The World
Bank has reported India as the fourth-largest economy in the world in terms of purchasing power parity, just ahead of Germany
in fifth place and competing for the top three positions with the United States, China, and Japan, respectively.
Second only to China's economy in terms of economic growth, the Indian economy registered 8.4% growth in 2005–2006. India's
GDP was reported as $796 billion and is estimated to grow by 9% in 2006–2007. Riding this steady wave of growth, the Indian
pharmaceutical industry rose in rank to become fourth in the world in terms of volume and 13th in the world in terms of value.
Of the approximately $550-billion global pharmaceutical market, India holds only 2% in terms of value but more than 8% in
terms of volume. Along with record-breaking growth, India hosts the most FDA-inspected and -approved manufacturing facilities,
and has filed more Drug Master Files than any other country besides the United States.
India's population of nearly 1.2 billion includes the third-largest English-speaking technical and scientific labor pool in
the world. For this reason, India has the jump on most countries in terms of human capital. Employing more than 30 million
people, India's pharmaceutical industry has approximately 3000 active pharmaceutical ingredient-manufacturing facilities,
nearly 5000 formulation facilities, and 2000 other pharmaceutical facilities. Out of these, 300 facilities are in the medium
to large range. Some subsectors, including biotechnology, bioinformatics, contract research and manufacturing services, clinical
research organizations, and pharmaceutical machinery manufacturing, are growing in tandem with the larger pharmaceutical industry,
as experienced human resources and investments spill over into these areas as well. It is therefore no wonder that India is
increasingly being called the "Gateway to Pharma".
The grass is always greener on the other side, however. Growing complaints from pharmaceutical producers about India's lack
of infrastructure, government-regulated price control of drugs, and resurfacing patent concerns are some of the issues at
stake. Despite the consistent double-digit growth of the last five years, India's pharmaceutical industry faces some problems.
Stringent international intellectual-property protections, good manufacturing practice measures, several successive acquisitions,
and cutthroat competition in the domestic generic drugs arena have slashed profit margins and greatly reduced research and
development budgets that are essential in moving up the value chain.
This report was prepared by Executive Country Reviews. Authors are Yaz Yazicioglu firstname.lastname@example.org
and Emmanuelle Berthemet email@example.com